Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

NCT05102721 is registered in ClinicalTrials.gov with Vaccinex Inc. as lead sponsor.

NCT NCT05102721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05102721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Vaccinex Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 10, 2022
Completion date
December 31, 2028
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma